EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GRI Bio's Enterprise Value is $-0.42 Mil.
GRI Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.99 Mil. Therefore, GRI Bio's EV-to-FCF for today is 0.05.
The historical rank and industry rank for GRI Bio's EV-to-FCF or its related term are showing as below:
GRI'
s EV-to-FCF Range Over the Past 10 Years
Min: -7.07 Med: 0 Max: 0.76
Current: 0.05
During the past 3 years, the highest EV-to-FCF of GRI Bio was 0.76. The lowest was -7.07. And the median was 0.00.
GRI's EV-to-FCF is ranked better than 93.11% of 392
companies
in the Biotechnology industry
Industry Median: 4.57
vs GRI: 0.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-04), GRI Bio's stock price is $0.41.
GRI Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-30.282. Therefore, GRI Bio's PE Ratio for today is At Loss.
GRI Bio EV-to-FCF Historical Data
The historical data trend for GRI Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, GRI Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where GRI Bio's EV-to-FCF falls into.
GRI Bio's current Enterprise Value is $-0.42 Mil.
GRI Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI Bio (NAS:GRI) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
GRI Bio's share price for today is $0.41.
GRI Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.282.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
GRI Bio EV-to-FCF Related Terms
Thank you for viewing the detailed overview of GRI Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRI has been successfully added to your 